

News Release

Company name: H.U. Group Holdings, Inc.
Representative: Shigekazu Takeuchi, Chairman, President and Group CEO
Securities code: 4544 Prime Market, Tokyo Stock Exchange

Fujirebio and Beckman Coulter Expand Partnership to Develop Patient-Friendly, Blood-based Neurodegenerative Disease Diagnostics

Tokyo, Japan, March 13 --- H.U. Group Holdings, Inc. today announced that Fujirebio Diagnostics AB¹ (Location: Mölndal, Sweden, hereinafter “FDAB”), a subsidiary of its wholly-owned subsidiary Fujirebio Holdings, Inc. (President and CEO: Goki Ishikawa; Head Office: Minato-ku, Tokyo), and Beckman Coulter, Inc. (President: Kevin O’Reilly, Head Office: Brea, California, hereinafter “Beckman Coulter”) have concluded an agreement to expand their existing partnership in the field of neurodegenerative diseases.

In 2023, Fujirebio and Beckman Coulter entered into a collaboration agreement² to establish a partnership for the development, manufacturing, and clinical adoption of neurodegenerative disease assays, including Alzheimer’s disease. Today’s announcement extends this partnership, including a pTau217 plasma assay and a Beta-Amyloid 1-42 plasma assay.

For more details, see [the press release from Fujirebio](#).

*1. Wholly-owned subsidiary of Fujirebio Diagnostics, Inc. (CEO: Monte Wiltse, Location: Malvern, Pennsylvania, United States) which is a wholly-owned subsidiary of Fujirebio Holdings, Inc.

*2. [Press release dated July 18, 2023, titled "Beckman Coulter and Fujirebio Partner to Bolster Access to Patient-friendly, Blood-based Alzheimer’s Disease Test Therapeutics"](#)

Contacts:

For media:

Public Relations Section, Public Relations/Sustainability Dept.

Phone: +81-3-6279-0884

Email: pr@hugp.com

For investors and analysts:

IR/SR Dept.

Phone: +81-3-6279-0926

Email: ir@hugp.com